Singapore, Oct. 29 -- The Health Sciences Authority received information related to the study titled 'ROSETTA CRC-203: A Blinded, Randomized Phase 2/3 Study of Pumitamig in Combination with Chemothera... Read More
Singapore, Oct. 29 -- The Health Sciences Authority received information related to the study titled 'A Phase 3, Multicenter, Randomized, Double-Blinded, Placebo-Controlled Study to Evaluate the Safet... Read More
Singapore, Oct. 29 -- The Health Sciences Authority received information related to the study titled 'A Phase III, Randomized, Open-Label, Multicenter, Global Study of Puxitatug Samrotecan (AZD8205) M... Read More
India, Oct. 29 -- Huntington Ingalls Industries, Inc. (HII) shares surged about 9% on Thursday morning after the shipbuilder reported higher third-quarter revenue and profit and raised its full-year s... Read More
Singapore, Oct. 29 -- The Health Sciences Authority received information related to the study titled 'A Phase 2, Randomized, Open-Label Dose Optimization and Phase 3, Randomized, Double-Blind, Placebo... Read More
Singapore, Oct. 29 -- The Health Sciences Authority received information related to the study titled 'A Phase 1 Open-Label Study to Determine the Effect of Injection Site on the Relative Bioavailabili... Read More
Singapore, Oct. 29 -- The Health Sciences Authority received information related to the study titled 'A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety ... Read More
Singapore, Oct. 29 -- The Health Sciences Authority received information related to the study titled 'A Phase 1, Randomized, Placebo-Controlled, Single and Multiple Ascending Dose-Escalation Study to ... Read More
Singapore, Oct. 29 -- The Health Sciences Authority received information related to the study titled 'A Phase 2 Platform Basket Study Evaluating Advanced Therapies in Subjects with Moderately to Sever... Read More
Singapore, Oct. 29 -- The Health Sciences Authority received information related to the study titled 'A Phase 3, Randomized, Open-Label Study of Rinzimetostat (ORIC-944) in Combination with Darolutami... Read More